LOS ANGELES -- (BUSINESS WIRE) -- Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced the launch of a new division that will specialize in the manufacturing and distribution of a proprietary line of dietary supplements.
The products, currently in the research and development phase, include a nasal decongestant, sleep aid, an appetite suppressant, a formula for pain and a formula that supports healthy cognitive performance. The products utilize the company’s patented targeted cellular technology platform to increase the effectiveness of milligram amounts of neurotransmitter precursors and “swish and swallow” system that is designed to allow digestive enzymes in saliva to initiate and facilitate digestion.
The first product is scheduled to be launched on November 1, 2013, and will be an oral dietary supplement featuring a proprietary sinuhealth blend designed to support healthy sinus and immune function, and help relieve nasal congestion, sinus pressure and runny nose associated with allergies and colds.
“We are pleased to announce the development of an over-the-counter product line and introduce a new technology that enhances the digestion processes by allowing salivary enzymes to function,” said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. “Our company is committed to innovating healthcare processes and providing physicians, patients, and health conscious consumers with the most effective and safe therapeutic options for health and wellness.”
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.